Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-NYM096
- Development stage
- Phase 1
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-NYM096 is a next-generation radiopharmaceutical theranostic agent developed by Peking Union Medical College Hospital for the treatment of metastatic clear cell renal cell carcinoma (ccRCC). The drug consists of NYM096, a small molecule ligand with high affinity for carbonic anhydrase 9 (CA9), labeled with the therapeutic beta-emitting radioisotope lutetium-177 (177Lu). CA9 is a cell-surface enzyme that is significantly overexpressed in the majority of ccRCC cases due to the inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene, making it an ideal target for site-specific delivery of radiation. NYM096 reportedly exhibits approximately 100-fold higher affinity for CA9 compared to its predecessor, NYM005. In clinical practice, it is utilized within a theranostic framework where patients are first screened using 68Ga-NYM096 PET/CT imaging to confirm CA9 expression before receiving the therapeutic 177Lu-NYM096 doses.
- Other names
- Lutetium (177Lu) NYM096
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on 177Lu-NYM096.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-NYM096.